Telmisartan w leczeniu nadciśnienia tętniczego — optymalny wybór zgodny z wytycznymi Polskiego Towarzystwa Nadciśnienia Tętniczego z 2015 roku

Abstract

In recent years emphasis in the treatment of hypertension has been put on the individualization of treatment. The recently published guidelines of the Polish Society of Hypertension list several clinical situations in which use of angiotensin II receptor blockers (ARBs) is indicated. Blockade of the renin-angiotensin- aldosterone system plays a pivotal role in the treatment of high blood pressure and prevention of target organ damage. Telmisartan is an angiotensin II receptor blocker displaying beneficial unique pharmacologic properties, metabolic effects, antihypertensive efficacy in monotherapy and combinations and good tolerance. Clinical studies confirm that telmisartan improves endothelial function, insulin sensitivity and lipid profiles, reduces arterial stiffness. In addition, telmisartan improves renal function and has potential beneficial effects on prevention of cerebrovascular disease. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) study has shown that telmisartan provides similar cardiovascular protection to ramipril in high-risk patients, while being better tolerated.